|
RXRB expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.22044604925031E-16 |
| Normal-vs-Stage2 |
4.01469999466997E-08 |
| Normal-vs-Stage3 |
1.11022302462516E-15 |
| Normal-vs-Stage4 |
2.8602997748095E-10 |
| Stage1-vs-Stage2 |
4.328800E-01 |
| Stage1-vs-Stage3 |
2.628100E-02 |
| Stage1-vs-Stage4 |
2.742800E-01 |
| Stage2-vs-Stage3 |
4.334100E-02 |
| Stage2-vs-Stage4 |
1.658420E-01 |
| Stage3-vs-Stage4 |
7.498200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
4.83500000003634E-06 |
| Normal-vs-Asian |
1.39310000202286E-08 |
| Caucasian-vs-AfricanAmerican |
3.157200E-01 |
| Caucasian-vs-Asian |
7.939600E-02 |
| AfricanAmerican-vs-Asian |
7.945600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.18984855091276E-12 |
| Normal-vs-Female |
1.62458935193399E-12 |
| Male-vs-Female |
2.951000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(41-60Yrs) |
2.89768209427166E-14 |
| Normal-vs-Age(61-80Yrs) |
1.55431223447522E-13 |
| Normal-vs-Age(81-100Yrs) |
5.474300E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.357000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.521400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.316200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.783400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.669400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.626400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.83929990629872E-10 |
| Classical-VS-Follicular |
8.682400E-01 |
| Classical-VS-Other |
4.796800E-01 |
| Classical-VS-Normal |
1.6251444634463E-12 |
| Tall-VS-Follicular |
2.50700000004045E-06 |
| Tall-VS-Other |
1.442350E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
6.317200E-01 |
| Follicular-VS-Normal |
5.16199971656306E-10 |
| Other-VS-Normal |
1.779150E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.10751424592581E-13 |
| Normal-vs-N1 |
4.94779772708398E-11 |
| N0-vs-N1 |
1.629790E-01 |
|
|
